Table 2.
GMT rSBA Titers by Serogroup for Subjects with Serology Data at Weeks 0, 4, 24, 28 and 72 by Treatment Arm
| SG | Group | Geometric Mean Titer* (95% Confidence Limits) | ||||
|---|---|---|---|---|---|---|
| Week 0 | Week 4 | Week 24 | Week 28 | Week 72 | ||
| A | Group 1: 1-Dose | 42 (25, 70) | 1911 (1135, 3216) | 287 (166, 497) | 205 (119, 355) | 127 (67, 240) |
| Group 1: 2-Doses | 32 (20, 52) | 1901 (1203, 3004) | 218 (127, 374) | 969 (633, 1483) | 281 (159, 497) | |
| Group 2 | 31 (9, 108) | 137 (32, 587) | 27 (8, 91) | 84 (23, 308) | 14 (4, 43) | |
| C | Group 1: 1-Dose | 8 (6, 10) | 196 (107, 356) | 30 (18, 49) | 24 (15, 37) | 14 (9, 23) |
| Group 1: 2-Doses | 6 (5, 8) | 131 (74, 234) | 21 (13, 32) | 174 (105, 290) | 38 (22, 64) | |
| Group 2 | 6 (3, 12) | 15 (4, 59) | 8 (4, 18) | 12 (4, 35) | 5 (3, 9) | |
| W-135 | Group 1: 1-Dose | 11 (8, 15) | 468 (307, 715) | 306 (193, 485) | 251 (156, 405) | 113 (67, 189) |
| Group 1: 2-Doses | 9 (7, 13) | 333 (215, 517) | 215 (129, 359) | 754 (488, 1165) | 167 (102, 275) | |
| Group 2 | 4 (n.a.) | 12 (5, 30) | 10 (5, 21) | 20 (7, 55) | 7 (4, 14) | |
| Y | Group 1: 1-Dose | 36 (23, 56) | 574 (368, 895) | 266 (174, 407) | 269 (172, 422) | 174 (107, 284) |
| Group 1: 2-Doses | 27 (18, 40) | 314 (201, 490) | 175 (114, 268) | 557 (380, 816) | 206 (133, 319) | |
| Group 2 | 5 (3, 9) | 24 (8, 77) | 17 (6, 46) | 32 (9, 108) | 13 (5, 33) | |
*
Due to assay limitations, exact titers could not be provided for results <8 or >131,072. For purposes of calculating medians and geometric mean titers, results <8 were set equal to 4 and those >131,072 were set equal to 262,144.
Sample sizes, range depending on SG:
Group 1, 1 dose: week 0 to 28: N=108–110, week 72: N=92–95
Group 1, 2-doses: week 0 to 28: N=112–115, week 72: N=95–98
Group 2: week 0 to 28: N=18–20, week 72: N=16–18